Cliff Asness's EDIT Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 1.57 M shares of Editas Medicine, Inc. (EDIT) worth $5.09 M, representing 0.00% of the portfolio. First purchased in 2017-Q4, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in EDIT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 726,300 shares. Largest reduction occurred in Q2 2025, reducing 253,021 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Editas Medicine (EDIT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Editas Medicine (EDIT) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +201,745 | Add 14.72% | 1.57 M | $3.24 |
| Q1 2026 | +726,300 | Add 112.75% | 1.37 M | $2.47 |
| Q4 2025 | -43,558 | Reduce 6.33% | 644,197 | $2.05 |
| Q3 2025 | -79,860 | Reduce 10.40% | 687,755 | $3.47 |
| Q2 2025 | -253,021 | Reduce 24.79% | 767,615 | $2.20 |
| Q1 2025 | -49,517 | Reduce 4.63% | 1.02 M | $1.16 |
| Q4 2024 | +693,956 | Add 184.47% | 1.07 M | $1.27 |
| Q3 2024 | +330,307 | Add 719.78% | 376,197 | $3.41 |
| Q2 2024 | +24,758 | Add 117.16% | 45,890 | $4.67 |
| Q1 2024 | +21,132 | New Buy | 21,132 | $7.42 |
| Q4 2023 | -36,933 | Sold Out | 0 | $0.00 |
| Q3 2023 | +9,158 | Add 32.97% | 36,933 | $7.80 |
| Q2 2023 | -28,433 | Reduce 50.59% | 27,775 | $8.23 |
| Q1 2023 | +23,446 | Add 71.56% | 56,208 | $7.25 |
| Q4 2022 | +32,762 | New Buy | 32,762 | $8.87 |
| Q2 2022 | -48,899 | Sold Out | 0 | $0.00 |
| Q1 2022 | +34,773 | Add 246.16% | 48,899 | $19.02 |
| Q4 2021 | -7,289 | Reduce 34.04% | 14,126 | $26.55 |
| Q3 2021 | +5,176 | Add 31.87% | 21,415 | $41.09 |
| Q2 2021 | -7,131 | Reduce 30.51% | 16,239 | $56.65 |
| Q1 2021 | +6,988 | Add 42.66% | 23,370 | $42.02 |
| Q4 2020 | -7,948 | Reduce 32.67% | 16,382 | $70.14 |
| Q3 2020 | -11,362 | Reduce 31.83% | 24,330 | $28.07 |
| Q2 2020 | -4,194 | Reduce 10.51% | 35,692 | $29.59 |
| Q1 2020 | +39,886 | New Buy | 39,886 | $19.83 |
| Q4 2018 | -20,014 | Sold Out | 0 | $0.00 |
| Q3 2018 | +4,221 | Add 26.73% | 20,014 | $31.83 |
| Q1 2018 | +7,812 | Add 97.88% | 15,793 | $33.18 |
| Q4 2017 | +7,981 | New Buy | 7,981 | $30.70 |
Cliff Asness's Editas Medicine Investment FAQs
Cliff Asness first purchased Editas Medicine, Inc. (EDIT) in Q4 2017, acquiring 7,981 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Editas Medicine, Inc. (EDIT) for 30 quarters since Q4 2017.
Cliff Asness's largest addition to Editas Medicine, Inc. (EDIT) was in Q1 2026, adding 1,370,497 shares worth $3.39 M.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 1,572,242 shares of Editas Medicine, Inc. (EDIT), valued at approximately $5.09 M.
As of the Q2 2026 filing, Editas Medicine, Inc. (EDIT) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Editas Medicine, Inc. (EDIT) was 1,572,242 shares, as reported at the end of Q2 2026.